Other: other court decision | Jan 30, 2025 | PAPER | BOARD |
Other: Fed Circuit mandate | Nov 13, 2024 | PAPER | BOARD |
Other: other court judgment
| Nov 13, 2024 | PAPER | BOARD |
EXPUNGED | Jan 24, 2023 | PAPER | BOARD |
Final Written Decision: original | Jan 24, 2023 | PAPER | BOARD |
Order: Order: Granting Joint Motion to Seal | Jan 24, 2023 | PAPER | BOARD |
Joint Motion to Seal the Final Written Decision | Jan 20, 2023 | PAPER | PETITIONER |
Redacted Final Written Decision | Jan 20, 2023 | EXHIBIT | PETITIONER |
Patent Owner's Notice of Appeal | Dec 23, 2022 | PAPER | PATENT OWNER |
Order: Directing the Submission of a Redacted Public Version of the Final Written Decision and Granting the Joint Motion to Expunge Certain Exhibits - 37 CFR 42.5 and 42.14 | Nov 1, 2022 | PAPER | BOARD |
Final Written Decision: Final Written Decision Determining All Challenged Claims Unpatentable 35 U.S.C. sec. 318a | Oct 25, 2022 | PAPER | BOARD |
Order: Dismissing Motion to Exclude as Moot 37 C.F.R. secs. 42.64c, 42.61a | Oct 25, 2022 | PAPER | BOARD |
Other: Hearing transcript | Sep 6, 2022 | PAPER | BOARD |
Joint Motion to Expunge | Aug 12, 2022 | PAPER | PETITIONER |
Patent Owner���s Reply in Support of its Motion to Exclude | Jul 18, 2022 | PAPER | PATENT OWNER |
Order: ORDER Granting Petitioners Motion to Seal 37 C.F.R. §§ 42.14 and 42.54 | Jul 13, 2022 | PAPER | BOARD |
Patent Owner's Second Updated Mandatory Notices | Jul 13, 2022 | PAPER | PATENT OWNER |
Patent Owner's Updated Power of Attorney (Novartis Pharma AG) | Jul 13, 2022 | PAPER | PATENT OWNER |
Patent Owner's Updated Power of Attorney (Novartis Pharmaceuticals Corporation) | Jul 13, 2022 | PAPER | PATENT OWNER |
Patent Owner's Updated Power of Attorney (Novartis Technology Corporation) | Jul 13, 2022 | PAPER | PATENT OWNER |
Petitioner's Opposition to Patent Owner's Motion to Exclude | Jul 12, 2022 | PAPER | PETITIONER |
Order: Granting Patent Owner's Third, Fourth, and Fifth Motions to Seal - Granting Patent Owner's Motion for Entry of Second Modified Default Protective Order - 37 CFR 42.14 and 42.54 | Jul 8, 2022 | PAPER | BOARD |
Joint Notice to Modify Date to Serve Demonstratives on Opposing Counsel | Jul 6, 2022 | PAPER | PATENT OWNER |
Patent Owner's Motion to Exclude Evidence | Jul 5, 2022 | PAPER | PATENT OWNER |
Preliminary Guidance Patent Owner's Motion to Amend (PUBLIC VERSION) | Jun 30, 2022 | PAPER | BOARD |
Setting Oral Argument 37 C.F.R. § 42.70 | Jun 27, 2022 | PAPER | BOARD |
Petitioners Request For Oral Argument | Jun 14, 2022 | PAPER | PETITIONER |
Patent Owner's Request for Oral Argument | Jun 14, 2022 | PAPER | PATENT OWNER |
Petitioner���s Updated Mandatory Notices Pursuant to 37 C.F.R �� 42.8 | Jun 6, 2022 | PAPER | PETITIONER |
PETITIONER'S THIRD OBJECTIONS TO ADMISSIBILITY OF EVIDENCE SUBMITTED BY PATENT OWNER | Jun 3, 2022 | PAPER | PETITIONER |
Notice of Certification of Word Count for Patent Owners' Surreply to Petitioner's Reply | May 27, 2022 | PAPER | PATENT OWNER |
Patent Owner's Notice of Withdrawal of Its Contingent Motion to Amend | May 26, 2022 | PAPER | PATENT OWNER |
Patent Owner's Fifth Motion to Seal | May 26, 2022 | PAPER | PATENT OWNER |
Patent Owner's Updated Exhibit List | May 26, 2022 | PAPER | PATENT OWNER |
Deposition Transcript of James Agalloco (May 4, 2022) [Redacted Version] | May 26, 2022 | EXHIBIT | PATENT OWNER |
Deposition Transcript of Joel M. Cohen (May 19, 2022) | May 26, 2022 | EXHIBIT | PATENT OWNER |
Deposition Transcript of Szilard Kiss, M.D., Vol. 2 (May 13, 2022) [Redacted Version] | May 26, 2022 | EXHIBIT | PATENT OWNER |
Deposition Transcript of Horst Koller, Vol. 2 (May 16, 2022) [Redacted Version] | May 26, 2022 | EXHIBIT | PATENT OWNER |
Deposition Transcript of James Agalloco (May 4, 2022) [Filed Under Seal] | May 26, 2022 | EXHIBIT | PATENT OWNER |
Deposition Transcript of Kenneth S. Graham (May 20, 2022) [Filed Under Seal] | May 26, 2022 | EXHIBIT | PATENT OWNER |
February 17, 2011 Email (Graham Ex. 1; REGITC00073676) [Filed Under Seal] | May 26, 2022 | EXHIBIT | PATENT OWNER |
August 4, 2011 Report (Graham Ex. 2; REGITC00092067) [Filed Under Seal] | May 26, 2022 | EXHIBIT | PATENT OWNER |
August 2, 2017 Email (Graham Ex. 7; REG_SDNY_01751250) [Filed Under Seal] | May 26, 2022 | EXHIBIT | PATENT OWNER |
Deposition Transcript of Szilard Kiss, M.D., Vol. 2 (May 13, 2022) [Filed Under Seal] | May 26, 2022 | EXHIBIT | PATENT OWNER |
Deposition Transcript of Gerrit Moyer (April 20, 2022), Case No. 1:20-cv-00690 (N.D. NY) [Filed Under Seal] | May 26, 2022 | EXHIBIT | PATENT OWNER |
Deposition Transcript of Horst Koller, Vol. 2 (May 16, 2022) [Filed Under Seal] | May 26, 2022 | EXHIBIT | PATENT OWNER |
Deposition Transcript of Lisa J. Cameron, Ph.D. (May 17, 2022)[Filed Under Seal] | May 26, 2022 | EXHIBIT | PATENT OWNER |
May 31, 2010 Email (Graham Ex. 3; REGITC00077226) [Filed Under Seal] | May 26, 2022 | EXHIBIT | PATENT OWNER |
May 16, 2011 Email (Graham Ex. 4; REGITC00088003) [Filed Under Seal] | May 26, 2022 | EXHIBIT | PATENT OWNER |
March 20, 2012 Email (Graham Ex. 5; REGITC00054921) [Filed Under Seal] | May 26, 2022 | EXHIBIT | PATENT OWNER |
March 13, 2012 Email (Graham Ex. 6; REGITC00260796) [Filed Under Seal] | May 26, 2022 | EXHIBIT | PATENT OWNER |
Patent Owner's Surreply to Petitioner's Reply - CONFIDENTIAL | May 26, 2022 | PAPER | PATENT OWNER |
Patent Owner's Surreply to Petitioner's Reply - REDACTED | May 26, 2022 | PAPER | PATENT OWNER |
Order: Other | May 25, 2022 | PAPER | BOARD |
Exhibit 3002 | May 25, 2022 | EXHIBIT | BOARD |
Preliminary Guidance Patent Owner's Motion to Amend | May 12, 2022 | PAPER | BOARD |
Patent Owners' Fourth Motion to Seal | May 11, 2022 | PAPER | PATENT OWNER |
Akers and Agalloco 2013, Overcoming Limitations of Vaporized Hydrogen Peroxide | May 11, 2022 | EXHIBIT | PATENT OWNER |
Agalloco 2008, Chapter in Pharmaceutical Manufacturing Handbook | May 11, 2022 | EXHIBIT | PATENT OWNER |
Deposition Transcript of James Agalloco (Feb. 16, 2021) [Filed Under
Seal] | May 11, 2022 | EXHIBIT | PATENT OWNER |
EXPUNGED | May 11, 2022 | EXHIBIT | PATENT OWNER |
Patent Owners' Updated Exhibit List | May 11, 2022 | PAPER | PATENT OWNER |
Petitioner's Updated Exhibit List | May 6, 2022 | PAPER | PETITIONER |
Patent Owners' Notice of Deposition of Horst Koller Under 37 C.F.R. Section 42.53 | May 4, 2022 | PAPER | PATENT OWNER |
Patent Owners' Notice of Deposition of Joel M. Cohen Under 37 C.F.R. Section 42.53 | May 4, 2022 | PAPER | PATENT OWNER |
Patent Owners' Notice of Deposition of Kenneth S. Graham Under 37 C.F.R. Section 42.53 | May 4, 2022 | PAPER | PATENT OWNER |
Patent Owners' Notice of Deposition of Lisa Cameron Under 37 C.F.R. Section 42.53 | May 4, 2022 | PAPER | PATENT OWNER |
Patent Owners' Notice of Deposition of W. Gregory Sawyer Under 37 C.F.R. Section 42.53 | May 4, 2022 | PAPER | PATENT OWNER |
Patent Owners' Notice of Deposition of James Agalloco Under 37 C.F.R. Section 42.53 | May 3, 2022 | PAPER | PATENT OWNER |
Patent Owners' Notice of Deposition of Szilard Kiss Under 37 C.F.R. Section 42.53 | May 3, 2022 | PAPER | PATENT OWNER |
Patent Owners' Objections To Admissibility of Evidence Submitted by Petitioner | Apr 22, 2022 | PAPER | PATENT OWNER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
REGITC00114439 - Regeneron Confidential Report | Apr 15, 2022 | EXHIBIT | PETITIONER |
REGITC00042686 - Vetter Confidential Report | Apr 15, 2022 | EXHIBIT | PETITIONER |
REGITC00264748 - Regeneron Confidential Report | Apr 15, 2022 | EXHIBIT | PETITIONER |
Declaration of James Agalloco | Apr 15, 2022 | EXHIBIT | PETITIONER |
Declaration of James Agalloco | Apr 15, 2022 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
Declaration of Dr. Kenneth Graham | Apr 15, 2022 | EXHIBIT | PETITIONER |
Declaration of Dr. Kenneth Graham | Apr 15, 2022 | EXHIBIT | PETITIONER |
REGITC00149282 ��� Regeneron Confidential Report | Apr 15, 2022 | EXHIBIT | PETITIONER |
Second Declaration of James L. Mullins, Ph.D. | Apr 15, 2022 | EXHIBIT | PETITIONER |
BD-ITC-000010 ��� Becton Dickinson Confidential Report | Apr 15, 2022 | EXHIBIT | PETITIONER |
Reply Declaration of Horst Koller | Apr 15, 2022 | EXHIBIT | PETITIONER |
STERIS_00000489 - Steris Report | Apr 15, 2022 | EXHIBIT | PETITIONER |
Reply Declaration of Horst Koller | Apr 15, 2022 | EXHIBIT | PETITIONER |
REGITC00122265 - Regeneron Confidential Report (1/9) | Apr 15, 2022 | EXHIBIT | PETITIONER |
Reply Declaration of Dr. Szilard Kiss | Apr 15, 2022 | EXHIBIT | PETITIONER |
Reply Declaration of Dr. Szilard Kiss | Apr 15, 2022 | EXHIBIT | PETITIONER |
REGITC00122265 ��� Regeneron Confidential Report (2/9) | Apr 15, 2022 | EXHIBIT | PETITIONER |
REGITC00122265 ��� Regeneron Confidential Report (3/9) | Apr 15, 2022 | EXHIBIT | PETITIONER |
Declaration of Lisa Cameron | Apr 15, 2022 | EXHIBIT | PETITIONER |
Declaration of Lisa Cameron | Apr 15, 2022 | EXHIBIT | PETITIONER |
Declaration of Joel M. Cohen | Apr 15, 2022 | EXHIBIT | PETITIONER |
REGITC00122265 - Regeneron Confidential Report (4/9) | Apr 15, 2022 | EXHIBIT | PETITIONER |
NOVITC(CH)02909828 - Novartis Confidential Presentation | Apr 15, 2022 | EXHIBIT | PETITIONER |
Deposition of Kim Cameron, Ph.D., (3/17/2022) | Apr 15, 2022 | EXHIBIT | PETITIONER |
REGITC00122265 - Regeneron Confidential Report (5/9) | Apr 15, 2022 | EXHIBIT | PETITIONER |
Deposition of Kim Cameron, Ph.D., (3/17/2022) | Apr 15, 2022 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
REGITC00122265 - Regeneron Confidential Report (6/9) | Apr 15, 2022 | EXHIBIT | PETITIONER |
Nishimoto, et al., Determination of Conditions for the Production Scale Sterilization of Prefilled Syringes, 57 PDA J Pharm Sci. & Tech, 378-386 (2003) | Apr 15, 2022 | EXHIBIT | PETITIONER |
Declaration of Gerrit Moyer | Apr 15, 2022 | EXHIBIT | PETITIONER |
REGITC00122265 - Regeneron Confidential Report (7/9) | Apr 15, 2022 | EXHIBIT | PETITIONER |
REGITC00122265 - Regeneron Confidential Report (8/9) | Apr 15, 2022 | EXHIBIT | PETITIONER |
BD-ITC-000101 - Becton Dickinson Confidential Sales
Information | Apr 15, 2022 | EXHIBIT | PETITIONER |
REGITC00122265 - Regeneron Confidential Report (9/9) | Apr 15, 2022 | EXHIBIT | PETITIONER |
NOVITC(CH)00137958 ��� Novartis Confidential Internal Memorandum | Apr 15, 2022 | EXHIBIT | PETITIONER |
BAUSCH00014 - Bausch Confidential FDA Correspondence | Apr 15, 2022 | EXHIBIT | PETITIONER |
REGITC00116953 - Vetter Confidential Report | Apr 15, 2022 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
REGITC01008782 - Vetter Confidential Report | Apr 15, 2022 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
Highlights of Prescribing Information,��� Lucentis, FDA, June 2006 | Apr 15, 2022 | EXHIBIT | PETITIONER |
Declaration of Lisa Cameron ��� List of Materials Considered | Apr 15, 2022 | EXHIBIT | PETITIONER |
REGITC00381349 - Regeneron Confidential Report (1/5) | Apr 15, 2022 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
REGITC00381349 - Regeneron Confidential Report (2/5) | Apr 15, 2022 | EXHIBIT | PETITIONER |
BAUSCH00035 - Bausch Confidential FDA Application (1/4) | Apr 15, 2022 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
REGITC00381349 - Regeneron Confidential Report (3/5) | Apr 15, 2022 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
REGITC00381349 - Regeneron Confidential Report (4/5) | Apr 15, 2022 | EXHIBIT | PETITIONER |
Deposition of James E. Malackowski, IPR2021-00816 (3/29/2022) | Apr 15, 2022 | EXHIBIT | PETITIONER |
REGITC00381349 - Regeneron Confidential Report (5/5) | Apr 15, 2022 | EXHIBIT | PETITIONER |
BAUSCH00035 - Bausch Confidential FDA Application (2/4) | Apr 15, 2022 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
Deposition of James E. Malackowski, IPR2021-00816 (3/29/2022) | Apr 15, 2022 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
Jesse David and Marion Stewart, Commercial Success: Economic Principles Applied to Patent Litigation | Apr 15, 2022 | EXHIBIT | PETITIONER |
BAUSCH00035 - Bausch Confidential FDA Application (3/4) | Apr 15, 2022 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
REGITC00255816 - Bayer Correspondence with EMEA | Apr 15, 2022 | EXHIBIT | PETITIONER |
REGITC00883958 - Regeneron Confidential Memorandum | Apr 15, 2022 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
BAUSCH00035 - Bausch Confidential FDA Application (4/4) | Apr 15, 2022 | EXHIBIT | PETITIONER |
REGITC00264472 - Regeneron Confidential Memorandum | Apr 15, 2022 | EXHIBIT | PETITIONER |
T. McNelis, ���New Designs: Licenses May Be Evidence of the Nonobviousness of an Invention,��� Fenwick & West LLP, 1998 | Apr 15, 2022 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
REGITC01066319 - Regeneron Confidential Memorandum | Apr 15, 2022 | EXHIBIT | PETITIONER |
Turbert, ���Anti-VEGF Treatments,��� American Academy of Ophthalmology, March 2, 2019 | Apr 15, 2022 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
REGITC00149657 - EMA Assessment Report | Apr 15, 2022 | EXHIBIT | PETITIONER |
REGITC00381924 - Regeneron Confidential Memorandum | Apr 15, 2022 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
BAUSCH00473 - Bausch FDA Correspondence | Apr 15, 2022 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
REGITC00041726 - Regeneron Confidential Presentation | Apr 15, 2022 | EXHIBIT | PETITIONER |
NOVITC(CH)00056469 - Novartis Confidential Presentation | Apr 15, 2022 | EXHIBIT | PETITIONER |
���Highlights of Prescribing Information,��� Lucentis, FDA, revised March 2018 | Apr 15, 2022 | EXHIBIT | PETITIONER |
REG_SDNY_02214433 - EMA Correspondence | Apr 15, 2022 | EXHIBIT | PETITIONER |
REGITC00160863 - Regeneron Confidential Memorandum | Apr 15, 2022 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
REGITC00110725 - Regeneron Confidential Emails | Apr 15, 2022 | EXHIBIT | PETITIONER |
REGITC00117031 - Regeneron Confidential FDA Correspondence | Apr 15, 2022 | EXHIBIT | PETITIONER |
NOVITC(CH)00217792 - Novartis Confidential Presentation | Apr 15, 2022 | EXHIBIT | PETITIONER |
REGITC01116755 - Confidential Sales Data | Apr 15, 2022 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
NOVITC(CH)00337297 - Novartis Confidential Presentation | Apr 15, 2022 | EXHIBIT | PETITIONER |
���Highlights of Prescribing Information,��� Eylea, FDA, revised March 2021 | Apr 15, 2022 | EXHIBIT | PETITIONER |
Sigg ITC Deposition Transcript (12/17/2020) | Apr 15, 2022 | EXHIBIT | PETITIONER |
Roettelle ITC Deposition Transcript (12/14/2020) | Apr 15, 2022 | EXHIBIT | PETITIONER |
NOVITC(CH)00217100 - Novartis Confidential Presentation | Apr 15, 2022 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
Petitioner's Motion to Seal | Apr 15, 2022 | PAPER | PETITIONER |
Sauer ITC Deposition Transcript (12/18/2020) | Apr 15, 2022 | EXHIBIT | PETITIONER |
BD-ITC-000069 - Becton Dickinson Presentation | Apr 15, 2022 | EXHIBIT | PETITIONER |
NOVITC(US)00016448 - Novartis Confidential Memorandum | Apr 15, 2022 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
Petitioner's Reply to Patent Owner's Response | Apr 15, 2022 | PAPER | PETITIONER |
Petitioner's Reply to Patent Owner's Response | Apr 15, 2022 | PAPER | PETITIONER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
Novartis Ophthalmics and Genentech announce development and commercialization agreement for age-related macular degeneration treatment, Lucentis(TM), Novartis Pharma AG press release, June 25, 2003 | Apr 15, 2022 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
VETTER_10001435_EN (Certified Translation) | Apr 15, 2022 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
Curriculum Vitae of Lisa Cameron | Apr 15, 2022 | EXHIBIT | PETITIONER |
Petitioner's Opposition to Patent Owner's Contingent Motion to Amend | Apr 15, 2022 | PAPER | PETITIONER |
Petitioner's Opposition to Patent Owner's Contingent Motion to Amend | Apr 15, 2022 | PAPER | PETITIONER |
Bayer HealthCare AG And Regeneron Pharmaceuticals, Inc. To Collaborate On VEGF Trap For The Treatment Of Eye Diseases Regeneron Retains U.S. Commercialization Rights, Receives $75 Million Upfront, October 19, 2006 | Apr 15, 2022 | EXHIBIT | PETITIONER |
Eylea Prefilled Syringe Now Available,��� Healio, December 12, 2019 | Apr 15, 2022 | EXHIBIT | PETITIONER |
REG_NDNY_00000004 - Gilead Sciences Inc. Form 10-K (1/6) | Apr 15, 2022 | EXHIBIT | PETITIONER |
REG_NDNY_00000004 - Gilead Sciences Inc. Form 10-K (2/6) | Apr 15, 2022 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
REG_NDNY_00000004 - Gilead Sciences Inc. Form 10-K (3/6) | Apr 15, 2022 | EXHIBIT | PETITIONER |
Mali Okada et al., Nonadherence or Nonpersistence to Intravitreal Injection Therapy for Neovascular Age-Related Macular Degeneration: A Mixed Methods Systematic Review,
Ophthalmology 128(2):234-247, August 5, 2020 | Apr 15, 2022 | EXHIBIT | PETITIONER |
REG_NDNY_00000004 - Gilead Sciences Inc. Form 10-K (4/6) | Apr 15, 2022 | EXHIBIT | PETITIONER |
Mali Okada, Tien Yin Wong, Paul Mitchell, et al., Defining Nonadherence and Nonpersistence to Anti���Vascular Endothelial Growth Factor Therapies in Neovascular Age-Related Macular Degeneration, JAMA Ophthalmology 139(7): 769-776, June 3,
2021 | Apr 15, 2022 | EXHIBIT | PETITIONER |
Turbert, What is Avastin?, American Academy of Ophthalmology, April 23, 2021 | Apr 15, 2022 | EXHIBIT | PETITIONER |
REGITC01117015 ��� Regeneron Confidential Presentation | Apr 15, 2022 | EXHIBIT | PETITIONER |
REG_NDNY_00000004 - Gilead Sciences Inc. Form 10-K (5/6) | Apr 15, 2022 | EXHIBIT | PETITIONER |
REG_NDNY_00000004 - Gilead Sciences Inc. Form 10-K (6/6) | Apr 15, 2022 | EXHIBIT | PETITIONER |
Highlights of Prescribing Information, Avastin, FDA, revised December 2020 | Apr 15, 2022 | EXHIBIT | PETITIONER |
Lambert, Rationale for practical medical device accelerated
aging programs in AAMI TIR 17, Radiation Physics and
Chemistry, 57 (2000) 349-353 | Apr 15, 2022 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
Callan Navitsky, The Regulation of Compounding Pharmacies, Retina Today, November/December 2012 | Apr 15, 2022 | EXHIBIT | PETITIONER |
Center for Drug Evaluation and Research, Application No. NDA
22-220, Trivaris | Apr 15, 2022 | EXHIBIT | PETITIONER |
Highlights of Prescribing Information, Beovu, revised March, 2022 | Apr 15, 2022 | EXHIBIT | PETITIONER |
Internet Archive WayBack Machine, Eyetech, Inc.: Science, Vision, Hope | Apr 15, 2022 | EXHIBIT | PETITIONER |
International Organization for Standardization, ISO 11040-5,
Prefilled syringes - Part 5: Plunger stoppers for injectables (3d.
ed. 2012) (���ISO 11040-5���) | Apr 15, 2022 | EXHIBIT | PETITIONER |
US FDA approves updated Novartis Beovu�� label, to include additional safety information, Novartis press release, June 11, 2020 | Apr 15, 2022 | EXHIBIT | PETITIONER |
���Highlights of Prescribing Information,��� Lucentis, FDA, revised February 2015 | Apr 15, 2022 | EXHIBIT | PETITIONER |
Angus Liu, Novartis calls off 3 Beovu trials testing more frequent dosing on concerns of vision-threatening side effect, FiercePharma, June 1, 2021 | Apr 15, 2022 | EXHIBIT | PETITIONER |
���Highlights of Prescribing Information,��� Eylea, FDA, revised August 2019 | Apr 15, 2022 | EXHIBIT | PETITIONER |
���Highlights of Prescribing Information,��� Eylea, FDA, revised September 2012 | Apr 15, 2022 | EXHIBIT | PETITIONER |
Highlights of Prescribing Information, Macugen, revised July 2011 | Apr 15, 2022 | EXHIBIT | PETITIONER |
���Highlights of Prescribing Information,��� Eylea, FDA, revised October 2014 | Apr 15, 2022 | EXHIBIT | PETITIONER |
Highlights of Prescribing Information, Susvimo, revised October 2021, | Apr 15, 2022 | EXHIBIT | PETITIONER |
���Highlights of Prescribing Information,��� Eylea, FDA, revised March 2015 | Apr 15, 2022 | EXHIBIT | PETITIONER |
���Highlights of Prescribing Information,��� Lucentis, FDA, revised February 2013 | Apr 15, 2022 | EXHIBIT | PETITIONER |
Susvimo 10 Mg/0.1Ml Implant Solution Macular Degeneration Treatment Agents-VEGF Antagonist Type- Uses, Side Effects, and More, WebMD | Apr 15, 2022 | EXHIBIT | PETITIONER |
���Highlights of Prescribing Information,��� Lucentis, FDA, revised April 2017 | Apr 15, 2022 | EXHIBIT | PETITIONER |
FDA Approves Genentech���s Susvimo, a First-of- Its-Kind Therapeutic Approach for Wet Age-Related Macular Degeneration (AMD), Genentech press release, October 22,
2021 | Apr 15, 2022 | EXHIBIT | PETITIONER |
���Highlights of Prescribing Information,��� Eylea, FDA, revised May 2019 | Apr 15, 2022 | EXHIBIT | PETITIONER |
Jonathan Gardner, Roche wins FDA approval for rival to Regeneron���s lucrative eye drug, BioPharma Dive, January 31, 2022 | Apr 15, 2022 | EXHIBIT | PETITIONER |
R. DeForest McDuff, Ryan C. Andrews, and Matt D. Brundage, Thinking Economically about Commercial Success, Landslide, 9(4): 1-5 (Mar./Apr. 2017) | Apr 15, 2022 | EXHIBIT | PETITIONER |
Highlights of Prescribing Information, Vabysmo, revised January 2022, | Apr 15, 2022 | EXHIBIT | PETITIONER |
Kevin L. Varghese, No Need to Neglect Nexus: Prosecution Lessons from FOX Factory v. SRAM, Intellectual Property & Tech. Law J., 32(6): 16 (June 2020) | Apr 15, 2022 | EXHIBIT | PETITIONER |
Jarosz and Vigil International In-house Counsel Journal Summer 2015 Assessing Commercial Success at the U.S. Patent Trial and Appeal Board | Apr 15, 2022 | EXHIBIT | PETITIONER |
Ernst R. Berndt et al., Information, Marketing, and Pricing in the U.S. Antiulcer Drug Market, The American Economic Review 85(2): 102-103 (1995) | Apr 15, 2022 | EXHIBIT | PETITIONER |
Excerpt of Opening Report of Szilard Kiss, M.D., ITC Inv. No. 337-TA-1207 (Jan. 22, 2021) | Apr 15, 2022 | EXHIBIT | PETITIONER |
Excerpt of Opening Report of Szilard Kiss, M.D., ITC Inv. No. 337-TA-1207 (Jan. 22, 2021) | Apr 15, 2022 | EXHIBIT | PETITIONER |
Excerpt of "Research Design: Model Specification,��� Reference Manual on Scientific Evidence, 3rd edition, National Academics
Press, 2011 | Apr 15, 2022 | EXHIBIT | PETITIONER |
Excerpt of Wooldridge, Jeffrey M., Econometric Analysis of Cross Section and Panel Data, MIT Press | Apr 15, 2022 | EXHIBIT | PETITIONER |
GlobalData Healthcare, The dominance of Eylea is expected to persist in the foreseeable future, Pharma Tech., July 1, 2020 (updated Dec. 1, 2021) | Apr 15, 2022 | EXHIBIT | PETITIONER |
Highlights of Prescribing Information, Lucentis, FDA, revised October 2016 | Apr 15, 2022 | EXHIBIT | PETITIONER |
Helen Marshall, Eylea (aflibercept), Medical News Today, February 16, 2020 | Apr 15, 2022 | EXHIBIT | PETITIONER |
REG_SDNY_03832114 - Confidential Sales Data | Apr 15, 2022 | EXHIBIT | PETITIONER |
Highlights of Prescribing Information, Lucentis, FDA, revised January 2017 | Apr 15, 2022 | EXHIBIT | PETITIONER |
REGITC01116432 - Confidential Sales Data | Apr 15, 2022 | EXHIBIT | PETITIONER |
Highlights of Prescribing Information, Lucentis, FDA, revised August 2012 | Apr 15, 2022 | EXHIBIT | PETITIONER |
REGITC00376214 - Novartis Completes Safety Review and Initiates Update to the Beovu Information Worldwide | Apr 15, 2022 | EXHIBIT | PETITIONER |
NOVITCCH00190794 ��� Novartis Confidential Letter | Apr 15, 2022 | EXHIBIT | PETITIONER |
Eric Sagonowsky, Novartis��� hot new eye drug Beovu tied to potential vision loss: experts (Feb. 24, 2020) | Apr 15, 2022 | EXHIBIT | PETITIONER |
Application No. 13382380 File History Excerpts | Apr 15, 2022 | EXHIBIT | PETITIONER |
Our Services, Vetter, accessed February 24, 2022 | Apr 15, 2022 | EXHIBIT | PETITIONER |
REGITC00375880 ��� Regeneron Confidential Agreement | Apr 15, 2022 | EXHIBIT | PETITIONER |
Excerpt of ITC Inv. No. 337-TA-1207, Complainants��� Substitute Pre-Hearing Brief (Public Version), March 30, 2021 | Apr 15, 2022 | EXHIBIT | PETITIONER |
GENEITC_1207-0003331 ��� Genentech Confidential Presentation | Apr 15, 2022 | EXHIBIT | PETITIONER |
Deposition of Karl R. Leinsing, IPR2021-00816 (3/24/2022) | Apr 15, 2022 | EXHIBIT | PETITIONER |
Deposition of Andrew F. Calman, IPR2021-00816 | Apr 15, 2022 | EXHIBIT | PETITIONER |
NOVITCCH02018792 - Novartis Confidential Presentation | Apr 15, 2022 | EXHIBIT | PETITIONER |
GILEAD00043 - Gilead Confidential Sales Information | Apr 15, 2022 | EXHIBIT | PETITIONER |
GILEAD00044 ��� Gilead Confidential Sales Information | Apr 15, 2022 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 15, 2022 | EXHIBIT | PETITIONER |
Deposition of John Dillberger, IPR2021-00816 | Apr 15, 2022 | EXHIBIT | PETITIONER |
Deposition of Michael J. Miller, IPR2021-00816 | Apr 15, 2022 | EXHIBIT | PETITIONER |
Deposition of Michael J. Miller, IPR2021-00816 | Apr 15, 2022 | EXHIBIT | PETITIONER |
Deposition of Marie Picci, IPR2021-00816 (3/31/2022) | Apr 15, 2022 | EXHIBIT | PETITIONER |
Deposition of Jeremy Wolfe, IPR2021-00816 (3/19/2022) | Apr 15, 2022 | EXHIBIT | PETITIONER |
Deposition of Juergen Sigg, IPR2021-00816 (4/12/2022) | Apr 15, 2022 | EXHIBIT | PETITIONER |
Kinney, Delivering Therapeutic siRNA, Drug Delivery Technology, Vol. 9, No. 2 (Feb. 2009) | Apr 15, 2022 | EXHIBIT | PETITIONER |
Joint Stipulation to Modify Due Dates 2 and 3 | Apr 8, 2022 | PAPER | PATENT OWNER |
Granting Patent Owner Motion for Admission Pro Hac Vice of John T. Bennett and Daniel P. Margolis 37 C.F.R. § 42.10 | Apr 5, 2022 | PAPER | BOARD |
Petitioner's Updated Mandatory Notices Pursuant to 37 C.F.R. 42.8 | Mar 30, 2022 | PAPER | PETITIONER |
Patent Owners��� Motion for Pro Hac Vice Admission of John T. Bennett and Daniel P. Margolis 37 C.F.R. �� 42.10 (c) | Mar 24, 2022 | PAPER | PATENT OWNER |
Ex. 2333 - Declaration of John T. Bennett in Support of Patent Owners��� Motion for Pro Hac Vice Admission of John T. Bennett Under 37 C.F.R. 42.10 (c) | Mar 24, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2334 - Declaration of Daniel P. Margolis in Support of Patent Owners Motion for Pro Hac Vice Admission of Daniel P. Margolis Under 37 C.F.R. 42.10 (c) | Mar 24, 2022 | EXHIBIT | PATENT OWNER |
Patent Owners Updated Exhibit List | Mar 24, 2022 | PAPER | PATENT OWNER |
Order: Appointing Commissioners and Direction of Submission | Mar 8, 2022 | PAPER | BOARD |
2022-03-07 - Petitioner's Updated Mandatory Notices | Mar 7, 2022 | PAPER | PETITIONER |
Panel Change Order | Mar 3, 2022 | PAPER | BOARD |
Patent Owner Novartis Pharma AG's Updated Power of Attorney | Mar 3, 2022 | PAPER | PATENT OWNER |
Patent Owner Novartis Pharmaceuticals Corporation's Updated Power of Attorney | Mar 3, 2022 | PAPER | PATENT OWNER |
Patent Owner Novartis Technology LLC's Updated Power of Attorney | Mar 3, 2022 | PAPER | PATENT OWNER |
Patent Owners' Updated Mandatory Notices | Mar 3, 2022 | PAPER | PATENT OWNER |
Joint Motion for the Appointment of Commissioners and Direction of Submission of Hague Convention Application | Mar 3, 2022 | PAPER | PATENT OWNER |
Ex. 2330 - Order appointing Swiss Commissioners, International Trade Commission Inv. No. 337-1207, Certain Pre-Filled Syringes for Intravitreal Injection and Components Thereof | Mar 3, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2331 - Order appointing Swiss Commissioners, Novartis Pharma AG et al v. Regeneron Pharmaceuticals, Inc., No. 1:20-cv00690-DH-CFH (NDNY) | Mar 3, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2332 - Proposed Order Appointing Commissioners | Mar 3, 2022 | EXHIBIT | PATENT OWNER |
Patent Owners' Updated Exhibit List | Mar 3, 2022 | PAPER | PATENT OWNER |
IPR2021-00816 Deposition Notice of Kimberly Cameron | Mar 2, 2022 | PAPER | PETITIONER |
IPR2021-00816 Deposition Notice of Juergen Sigg | Mar 2, 2022 | PAPER | PETITIONER |
IPR2021-00816 Deposition Notice of Marie Picci | Mar 2, 2022 | PAPER | PETITIONER |
IPR2021-00816 Deposition Notice of Karl Leinsing | Mar 2, 2022 | PAPER | PETITIONER |
IPR2021-00816 Deposition Notice of Michael Miller | Mar 2, 2022 | PAPER | PETITIONER |
Deposition Notice of Andrew F. Calman | Mar 2, 2022 | PAPER | PETITIONER |
Deposition Notice of John Dillberger | Mar 2, 2022 | PAPER | PETITIONER |
Deposition Notice of James Malackowski | Mar 2, 2022 | PAPER | PETITIONER |
Deposition Notice of Jeremy Wolfe | Mar 2, 2022 | PAPER | PETITIONER |
Petitioner's Updated Power of Attorney | Feb 15, 2022 | PAPER | PETITIONER |
Petitioner's Updated Mandatory Notices | Feb 15, 2022 | PAPER | PETITIONER |
ORDER Granting Petitioners Motion for Pro Hac Vice Admission of Robert Vlasis 37 C.F.R. sec 42.10 | Jan 27, 2022 | PAPER | BOARD |
IPR2021-00816, 2022-01-25, Motion for Pro Hac Vice - Robert Vlasis | Jan 26, 2022 | PAPER | PETITIONER |
PETITIONER���S SECOND OBJECTIONS TO ADMISSIBILITY OF EVIDENCE SUBMITTED BY PATENT OWNER | Jan 26, 2022 | PAPER | PETITIONER |
IPR2021-00816, 2022-01-25, Updated Exhibit List | Jan 25, 2022 | PAPER | PETITIONER |
Ex. 1098, Declaration of Robert T. Vlasis ISO Motion for Pro Hac Vice | Jan 25, 2022 | EXHIBIT | PETITIONER |
Ex. 1099, Bio for Robert T. Vlasis - Weil Gotshal Manges | Jan 25, 2022 | EXHIBIT | PETITIONER |
Ex. 2208 ��� Cameron Declaration [PUBLIC REDACTED VERSION] | Jan 20, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2257 - Kiss Depo Tr. | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2194 - Overcashier Dep. Tr. Part 1 of 2 [FILED UNDER SEAL] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Exhibit 2194- Overcashier Dep. Tr. Part 2 of 2 [FILED UNDER SEAL] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2161 - Roche Finance Report for 2016 | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2163 - Roche Finance Report for 2019 | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2258 - Macular Degeneration Treatments | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2259 - Avastin Prescribing Information Part 1 of 4 | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2259 - Avastin Prescribing Information Part 2 of 4 | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2259 - Avastin Prescribing Information Part 3 of 4 | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2125 - Lucentis Prescribing Information, revised March 2018 | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2162 - Roche Finance Report for 2014 | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2259 - Avastin Prescribing Information Part 4 of 4 | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2260 - Comparison of Anti VEGF Treatments | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2261 - Age-Related Macular Degeneration Facts & Figures | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2262 - FDA Approves Avastin Article | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2264 - Roche March 22, 2018 Investor Update | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2265 - Genentech, Inc. Form 10K for the period ending 12312003 | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2266 - FDA Approves Lucentis Article | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2269 - FDA Approves Eylea Article | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2270 - FDA Approves Eylea PFS Article | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2271 - Prefilled Syringe Delivery of Intravitreal Anti-VEGF Medications | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2272 - Excerpted Chris Simms Transcript | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2273 - Roche Finance Report for 2011 | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2274 - Roche Finance Report for 2012 Part 1 of 2 | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2274 - Roche Finance Report for 2012 Part 2 of 2 | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2275 - Roche Finance Report for 2015 Part 1 of 2 | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2275 - Roche Finance Report for 2015 Part 2 of 2 | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2276 - Roche Finance Report for 2017 Part 1 of 3 | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2276 - Roche Finance Report for 2017 Part 2 of 3 | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2276 - Roche Finance Report for 2017 Part 3 of 3 | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2277 - Treatments for Wet AMD | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2142 - NOVITC(CH)01494800 [PUBLIC REDACTED VERSION] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2119 - NOVITC(CH)00003455 [PUBLIC REDACTED VERSION] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
EXPUNGED | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2128 - NOVITC(CH)00167663 [PUBLIC REDACTED VERSION] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2130 - NOVITC(CH)00169036 [PUBLIC REDACTED VERSION] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2138 - NOVITC(CH)00217650 [PUBLIC REDACTED VERSION] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2139 - NOVITC(CH)00810847 [PUBLIC REDACTED VERSION] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2141 - NOVITC(CH)00880433 [PUBLIC REDACTED VERSION] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2144 - NOVITC(CH)01498292 [PUBLIC REDACTED VERSION] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2146 - NOVITC(CH)01863785 [PUBLIC REDACTED VERSION] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2147 - NOVITC(CH)01906307 [PUBLIC REDACTED VERSION] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2118 - NOVITC(CH)00002720 [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2152 - NOVITC(US)00000788 [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2153 - NOVITC(US)00000792 [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2154 - NOVITC(US)00000795 [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2155 - NOVITC(US)00006151 [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2156 - NOVITC(US)00006173 [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2157 - NOVITC(US)00006182 [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2158 - NOVITC(US)00006196 [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2159 - NOVITC(US)00006213 [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2164 - Roche Finance Report 2013 Part 1 of 2 | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Exhibit 2164 - Roche Finance Report 2013 Part 2 of 2 | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2166 - NOVITC(US)00389194 [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex.. 2167 - NOVITC(US)00394737 [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2168 - NOVITC(US)00395564 [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2169 - NOVITC(US)00395565 [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2170 - NOVITC(US)00507243 [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2171 - NOVITC(US)00697489 [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2172 - NOVITC(US)00718202 [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2185 - Ansel 1995 | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2186 - Lachman 1986 | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2187 - ANSIAAMI ST67-2011 | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2188 - ISO 14161 | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2190 - Bash and Gould 1984 | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2191 - CFR 2004 | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2192 - CFR 2008 | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2193 - CFR 2021 | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2195 - Poche 2019 | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2196 - ISO 10993-7-2008 | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2197 - Eylea PFS Label Aug 2019 | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2203 - Declaration of Michael J Miller [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2204 - Calman Declaration [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2206 - Declaration of Juergen Sigg [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2300 - Yoon 2009 | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2121 - NOVITC(CH)00005765 [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Patent Owner's Updated Exhibit List | Jan 19, 2022 | PAPER | PATENT OWNER |
Ex. 2120 - NOVITC(CH)00004818 [Public Redacted Version - Replacement] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2123 - NOVITC(CH)00007283 [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2124 - NOVITC(CH)00008409 [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2126 - NOVITC(CH)00054063 [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2129 - NOVITC(CH)00168961 [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2131 - NOVITC(CH)00170304 [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2205 - Malackowski Declaration [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2133 - NOVITC(CH)00170896 [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2134 - NOVITC(CH)00170915 [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2136 - NOVITC(CH)00217349 [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2137 - NOVITC(CH)00217646 [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2140 - NOVITC(CH)00874056 [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2143 - NOVITC(CH)01495912 [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2145 - NOVITC(CH)01863737 [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2148 - NOVITC(CH)02022271 [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2150 - NOVITC(CH)02929814 [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2201 - Supplemental Leinsing [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2254 - NOVITC(CH)00885630 [Public Redacted Version] | Jan 19, 2022 | EXHIBIT | PATENT OWNER |
Novartis Pharma AG, Novartis Technology LLC, and Novartis Pharmaceuticals Corporation's Patent Owner Response [PUBLIC REDACTED VERSION] | Jan 19, 2022 | PAPER | PATENT OWNER |
Joint Stipulation to Modify Due Dates 1 and 2 | Jan 19, 2022 | PAPER | PATENT OWNER |
IPR2021-00816, Petitioner's Updated Power of Attorney | Jan 18, 2022 | PAPER | PETITIONER |
2022-01-18, Petitioner's Updated Exhibit List | Jan 18, 2022 | PAPER | PETITIONER |
Ex. 1097, 2022-01-06 Telephonic Conference | Jan 18, 2022 | EXHIBIT | PETITIONER |
Ex. 2116 - Genentech Press Release | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2117 - Genentech Press Release | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2125 - Lucentis Prescribing Information | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2160 - Lucentis PFS Letter and Label | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2161 - Roche Finance Report for 2016 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2162 - Roche Finance Report for 2014 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2163 - Roche Finance Report for 2019 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2174 - WHO Guidelines on Packaging for Pharmaceutical Products | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2176 - Boven 2005 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2177 - Tzannis 1996 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2178 - Markovic 2009 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2179 - Markovic 2011 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2180 - Silver 2008 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2175 - Akers 2010 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2181 - ISO-10993-1-2009 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2182 - Helmus 2008 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2183 - FDA Use of ISO-10993 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2184 - Rathore 2008 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2198 - Venook Declaration | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2199 - ISO 11137 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2200 - Von Woedtke and Kramer | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2253 - Jones 2005 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2255 - Teng 2012 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2278 - Eylea PFS PBS Listed, Indications Expanded ��� minivision | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2279 - Macugen European Medicines Agency - EPAR website | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
EXPUNGED | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
EXPUNGED | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
EXPUNGED | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
EXPUNGED | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
EXPUNGED | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2215 - Storey et al. 2019 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
EXPUNGED | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
EXPUNGED | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2227 - Application No. 13/750,352 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2228 - FDA Guidance for Industry ��� Q1A (R2) Stability Testing of New Drug Substances and Products (2003) | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
EXPUNGED | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
EXPUNGED | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2231 - EYLEA Approval Letter | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2232 - Freund 2006 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2224 - DSR5092D [PUBLIC REDACTED VERSION] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Exhibit 2099 - GENEITC_1207-0000030 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Exhibit 2100 - GENEITC_1207-0001660 Part 1 of 3 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Exhibit 2100 - GENEITC_1207-0001660 Part 2 of 3 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Exhibit 2100 - GENEITC_1207-0001660 Part 3 of 3 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Exhibit 2101 - GENEITC_1207-0001864 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Exhibit 2102 - GENEITC_1207-0002423 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Exhibit 2103 - GENEITC_1207-0002825 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Exhibit 2104 - GENEITC_1207-0003003 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Exhibit 2105 - GENEITC_1207-0003160 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Exhibit 2106 - GENEITC_1207-0003163 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Exhibit 2107 - GENEITC_1207-0003412 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Exhibit 2108 - GENEITC_1207-0003418 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Exhibit 2109 - GENEITC_1207-0003503 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Exhibit 2110 - GENEITC_1207-0003545 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Exhibit 2111 - GENEITC_1207-0003551 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Exhibit 2112 - GENEITC_1207-0003675 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Exhibit 2113 - GENEITC_1207-0003683 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Exhibit 2114 - GENEITC_1207-0003704 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Exhibit 2115 - GENEITC_1207-0002409 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2125 - Lucentis Prescribing Information, revised March 2018 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2256 - Calman CV | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2280 - Michaud 2014 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2281 - Krzystolik 2002 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2282 - FDA Approval for Macugen | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2283 - FDA Approved Drugs Page for Macugen | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2284 - Rich 2006 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2285 - Avastin FDA Label | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2286 - Eylea FDA approval letter | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2287 - Federman 1998 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2288 - Nguyen 1992 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2289 - Scott 2003 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2291 - Rosenberg 2006 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2292 - Charles 2009 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2293 - Stepien 2009 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2294 - Beovu approval letter | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2295 - Mittra 2006 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2296 - Santaella 2007 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2297 - Abbasi 2009 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2298 - Schatz 1986 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2299 - Peck 2010 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2301 - Lang 2007 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2302 - Chen 2013 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2303 - Sarao 2014 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2304 - Baudin 2018 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2305 - Wilson 2013 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2306 - Kamjoo 2021 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2307 - Jonas 2003 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2308 - Ramulu 2010 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2309 - Asbell 2016 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2310 - EVS Study Group 1995 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2311 - Dossarps 2015 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2312 - Klein 2009 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2313 - Green Simms 2011 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2314 - McCannell 2011 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2315 - Shimada 2013 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2316 - Levinson 2018 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2317 - Gallemore 2006 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2318 - Ip 2004 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2319 - Gedde 2006 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2320 - Riedel 1990 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2321 - Thompson 2021 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2322 - Kahook 2010 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2326 - FDA Eylea PFS Approval Letter | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2209 - Wolfe Declaration | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2202 - Declaration of John E. Dillberger | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2203 - Declaration of Michael J Miller [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2206 - Declaration of Juergen Sigg [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2323 - Second Modified Protective Order | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2324 - Redline of Second Modified Protective Order | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2325 - Declaration of Martina Athanas | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2224 - DSR5092D [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2119 - NOVITC(CH)00003455 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2121 - NOVITC(CH)00005765 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2124 - NOVITC(CH)00008409 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2126 - NOVITC(CH)00054063 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2128 - NOVITC(CH)00167663 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2129 - NOVITC(CH)00168961 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2130 - NOVITC(CH)00169036 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2131 - NOVITC(CH)00170304 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2132 - NOVITC(CH)00170859 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2133 - NOVITC(CH)00170896 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2134 - NOVITC(CH)00170915 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2136 - NOVITC(CH)00217349 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2137 - NOVITC(CH)00217646 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2138 - NOVITC(CH)00217650 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2139 - NOVITC(CH)00810847 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2140 - NOVITC(CH)00874056 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2141 - NOVITC(CH)00880433 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2142 - NOVITC(CH)01494800 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2143 - NOVITC(CH)01495912 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2144 - NOVITC(CH)01498292 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2145 - NOVITC(CH)01863737 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2146 - NOVITC(CH)01863785 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2147 - NOVITC(CH)01906307 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2148 - NOVITC(CH)02022271 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2150 - NOVITC(CH)02929814 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2155 - NOVITC(US)00006151 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2156 - NOVITC(US)00006173 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2157 - NOVITC(US)00006182 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2158 - NOVITC(US)00006196 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2159 - NOVITC(US)00006213 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2166 - NOVITC(US)00389194 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2167 - NOVITC(US)00394737 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2170 - NOVITC(US)00507243 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2171 - NOVITC(US)00697489 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2172 - NOVITC(US)00718202 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2254 - NOVITC(CH)00885630 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Novartis Pharma AG, Novartis Technology LLC, and Novartis Pharmaceuticals Corporation's Patent Owner Response | Jan 18, 2022 | PAPER | PATENT OWNER |
Ex. 2062 - Jeffrey Salling Declaration | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
NOVITC(CH)00004818 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2122 - NOVITC(CH)00006074 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2123 - NOVITC(CH)00007283 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2168 - NOVITC(US)00395564 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2169 - NOVITC(US)00395565 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2189 - Koller IPR Dep. Tr. Part 1 of 2 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2189 - Koller IPR Dep. Tr. Part 2 of 2 | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2201 - Leinsing Supplemental Declaration [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2204 - Calman Declaration [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Patent Owner's Contingent Motion to Amend Under 37 C.F.R. Section 42.121 [PUBLIC REDACTED VERSION] | Jan 18, 2022 | PAPER | PATENT OWNER |
Patent Owner's Contingent Motion to Amend Under 37 C.F.R. Section 42.121 [FILED UNDER SEAL] | Jan 18, 2022 | PAPER | PATENT OWNER |
EXPUNGED | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
EXPUNGED | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Patent Owners' Third Motion to Seal and Motion for a Modified Default Protective Order | Jan 18, 2022 | PAPER | PATENT OWNER |
Ex. 2168 - NOVITC(US)00395564 [FILED UNDER SEAL] | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
Ex. 2205 - Malackowski Declaration [FILED UNDER SEAL]_ | Jan 18, 2022 | EXHIBIT | PATENT OWNER |
IPR2021-00816, Petitioner's Updated Mandatory Notices | Jan 7, 2022 | PAPER | PETITIONER |
Order: Granting Patent Owner's Motion for Admission Pro Hac Vice of Nicholas K. Mitrokostas | Jan 5, 2022 | PAPER | BOARD |
Order: Granting Petitioner's Motion for Admission Pro Hac Vice of Petra Scamborova | Jan 5, 2022 | PAPER | BOARD |
Patent Owners Notice of Deposition of Szilard Kiss Under C.F.R. Section 42.53 | Dec 23, 2021 | PAPER | PATENT OWNER |
Patent Owners Motion for Pro Hac Vice Admission of Nicholas K. Mitrokostas Under 37 C.F.R. Section 42.10(c) | Dec 22, 2021 | PAPER | PATENT OWNER |
Exhibit 2098 - Declaration of Nicholas K. Mitrokostas in Support of Patent Owners Motion for Pro Hac Vice Admission of Nicholas K. Mitrokostas Under 37 C.F.R. Section 42.10(c) | Dec 22, 2021 | EXHIBIT | PATENT OWNER |
Patent Owners Updated Exhibit List | Dec 22, 2021 | PAPER | PATENT OWNER |
Motion: PHV | Dec 22, 2021 | PAPER | PETITIONER |
Notice: exhibit list | Dec 22, 2021 | PAPER | PETITIONER |
Declaration of Petra Scamborova | Dec 22, 2021 | EXHIBIT | PETITIONER |
P. Scamborova LinkedIn Profile | Dec 22, 2021 | EXHIBIT | PETITIONER |
Petitioner's Corrected First Supplemental Exhibit List | Dec 3, 2021 | PAPER | PETITIONER |
Patent Owners' Notice of Deposition of Horst Koller Under C.F.R. Section 42.53 | Dec 2, 2021 | PAPER | PATENT OWNER |
Order: Granting Patent Owner's Second Motion to Seal - 37 CFR 42.14 and 42.54 | Nov 30, 2021 | PAPER | BOARD |
EXPUNGED | Nov 23, 2021 | PAPER | PETITIONER |
EXPUNGED | Nov 23, 2021 | PAPER | PETITIONER |
EXPUNGED | Nov 23, 2021 | EXHIBIT | PETITIONER |
EXPUNGED | Nov 23, 2021 | EXHIBIT | PETITIONER |
EXPUNGED | Nov 23, 2021 | EXHIBIT | PETITIONER |
EXPUNGED | Nov 23, 2021 | EXHIBIT | PETITIONER |
Patent Owners Second Motion to Seal | Nov 19, 2021 | PAPER | PATENT OWNER |
Exhibit 2097 - Declaration of Martina Athanas In Support of Novartis���s Second Motion to Seal | Nov 19, 2021 | EXHIBIT | PATENT OWNER |
Exhibit 2063 [PUBLIC REDACTED VERSION] | Nov 19, 2021 | EXHIBIT | PATENT OWNER |
Exhibit 2064 [PUBLIC REDACTED VERSION] | Nov 19, 2021 | EXHIBIT | PATENT OWNER |
Exhibit 2066 [PUBLIC REDACTED VERSION] | Nov 19, 2021 | EXHIBIT | PATENT OWNER |
Exhibit 2067 [PUBLIC REDACTED VERSION] | Nov 19, 2021 | EXHIBIT | PATENT OWNER |
Exhibit 2068 [PUBLIC REDACTED VERSION] | Nov 19, 2021 | EXHIBIT | PATENT OWNER |
Exhibit 2069 [PUBLIC REDACTED VERSION] | Nov 19, 2021 | EXHIBIT | PATENT OWNER |
Exhibit 2070 [PUBLIC REDACTED VERSION] | Nov 19, 2021 | EXHIBIT | PATENT OWNER |
Exhibit 2071 [PUBLIC REDACTED VERSION] | Nov 19, 2021 | EXHIBIT | PATENT OWNER |
Exhibit 2072 [PUBLIC REDACTED VERSION] | Nov 19, 2021 | EXHIBIT | PATENT OWNER |
Exhibit 2073 [PUBLIC REDACTED VERSION] | Nov 19, 2021 | EXHIBIT | PATENT OWNER |
Exhibit 2074 [PUBLIC REDACTED VERSION] | Nov 19, 2021 | EXHIBIT | PATENT OWNER |
Exhibit 2075 [PUBLIC REDACTED VERSION] | Nov 19, 2021 | EXHIBIT | PATENT OWNER |
Exhibit 2076 [PUBLIC REDACTED VERSION] | Nov 19, 2021 | EXHIBIT | PATENT OWNER |
Exhibit 2077 [PUBLIC REDACTED VERSION] | Nov 19, 2021 | EXHIBIT | PATENT OWNER |
Exhibit 2078 [PUBLIC REDACTED VERSION] | Nov 19, 2021 | EXHIBIT | PATENT OWNER |
Exhibit 2079 [PUBLIC REDACTED VERSION] | Nov 19, 2021 | EXHIBIT | PATENT OWNER |
Exhibit 2080 [PUBLIC REDACTED VERSION] | Nov 19, 2021 | EXHIBIT | PATENT OWNER |
Exhibit 2081 [PUBLIC REDACTED VERSION] | Nov 19, 2021 | EXHIBIT | PATENT OWNER |
Exhibit 2082 [PUBLIC REDACTED VERSION] | Nov 19, 2021 | EXHIBIT | PATENT OWNER |
Exhibit 2083 [PUBLIC REDACTED VERSION] | Nov 19, 2021 | EXHIBIT | PATENT OWNER |
Exhibit 2084 [PUBLIC REDACTED VERSION] | Nov 19, 2021 | EXHIBIT | PATENT OWNER |
Exhibit 2085 [PUBLIC REDACTED VERSION] | Nov 19, 2021 | EXHIBIT | PATENT OWNER |
Exhibit 2086 [PUBLIC REDACTED VERSION] | Nov 19, 2021 | EXHIBIT | PATENT OWNER |
Exhibit 2087 [PUBLIC REDACTED VERSION] | Nov 19, 2021 | EXHIBIT | PATENT OWNER |
Exhibit 2088 [PUBLIC REDACTED VERSION] | Nov 19, 2021 | EXHIBIT | PATENT OWNER |
Patent Owners Updated Exhibit List | Nov 19, 2021 | PAPER | PATENT OWNER |
Petitioner's Objections to Admissibility of Evidence Submitted by Patent Owner | Nov 9, 2021 | PAPER | PETITIONER |
Patent Owners Objections to Admissibility of Evidence Submitted by Petitioners | Nov 9, 2021 | PAPER | PATENT OWNER |
ORDER Denying Patent Owners Motion to Seal 37 C.F.R. sec s 42.14 and 42.54 | Oct 28, 2021 | PAPER | BOARD |
Institution Decision: Grant | Oct 26, 2021 | PAPER | BOARD |
Order: Scheduling Order | Oct 26, 2021 | PAPER | BOARD |
Novartis Pharma AG, Novartis Technology LLC, and Novartis Pharmaceuticals Corporation���s Patent Owner Sur-Reply | Aug 27, 2021 | PAPER | PATENT OWNER |
Exhibit 2093 | Aug 27, 2021 | EXHIBIT | PATENT OWNER |
Exhibit 2094 | Aug 27, 2021 | EXHIBIT | PATENT OWNER |
Exhibit 2095 | Aug 27, 2021 | EXHIBIT | PATENT OWNER |
Exhibit 2096 | Aug 27, 2021 | EXHIBIT | PATENT OWNER |
E-Mail | Aug 27, 2021 | EXHIBIT | BOARD |
Petitioner's Reply to Patent Owner's Preliminary Response | Aug 20, 2021 | PAPER | PETITIONER |
Text Minute Entry re Rule 16 Conference held on August 18, 2021, Novartis Pharma AG et al v. Regeneron Pharma., Inc., No. 1:20-cv-00690 (N.D.N.Y. Aug. 18, 2021) | Aug 20, 2021 | EXHIBIT | PETITIONER |
Novartis Pharma AG, Novartis Technology LLC, and Novartis Pharmaceuticals Corporation���s Patent Owner Preliminary Response | Jul 28, 2021 | PAPER | PATENT OWNER |
Patent Owners��� Unopposed Motion for a Modified Default Protective Order | Jul 28, 2021 | PAPER | PATENT OWNER |
Patent Owners��� Motion to Seal | Jul 28, 2021 | PAPER | PATENT OWNER |
Declaration of Karl R. Leinsing, PE | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
Declaration of Marie Picci [Filed Under Seal] | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
Declaration of Marie Picci [Public Redacted Version] | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2003 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2004 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2005 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2006 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2007 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2008 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2009 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2010 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2011 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2012 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2013 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2014 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2015 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2016 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2017 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2018 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2019 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2020 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2021 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2022 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2023 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2024 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2025 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2026 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2027 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2028 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2029 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2030 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2031 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2032 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2033 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2034 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2035 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2036 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2041 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2042 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2044 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2045 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2046 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2047 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2048 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2049 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2050 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2051 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2052 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2053 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2054 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2055 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2056 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2057 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2058 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2059 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2060 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2061 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
Declaration of Jeffrey Salling | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2063 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2064 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2065 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2066 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2067 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2068 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2069 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2070 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2071 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2072 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2073 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2074 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2075 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2076 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2077 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2078 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2079 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2080 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2081 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2082 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2083 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2084 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2085 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2086 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2087 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2088 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2089 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2090 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2091 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
2092 | Jul 28, 2021 | EXHIBIT | PATENT OWNER |
Patent Owner's Submission of Mandatory Notice Information Under 37 C.F.R. �� 42.8(a)(2) | May 7, 2021 | PAPER | PATENT OWNER |
Patent Owner Novartis Pharma AG's Power of Attorney | May 7, 2021 | PAPER | PATENT OWNER |
Patent Owner Novartis Pharmaceutical Corporation's Power of Attorney | May 7, 2021 | PAPER | PATENT OWNER |
Patent Owner Novartis Technology LLC's Power of Attorney | May 7, 2021 | PAPER | PATENT OWNER |
Notice of Accord Filing Date | Apr 28, 2021 | PAPER | BOARD |
PETITION FOR INTER PARTES REVIEW OF U.S. PATENT NO. 9,220,631 | Apr 16, 2021 | PAPER | PETITIONER |
POWER OF ATTORNEY FOR PETITIONER REGENERON PHARMACEUTICALS, INC. | Apr 16, 2021 | PAPER | PETITIONER |
U.S. Patent No. 9,220,631 (���the ���631 Patent���) | Apr 16, 2021 | EXHIBIT | PETITIONER |
Prosecution File History of U.S. Patent No. 9,220,631, part 1 | Apr 16, 2021 | EXHIBIT | PETITIONER |
Prosecution File History of U.S. Patent No. 9,220,631, part 2 | Apr 16, 2021 | EXHIBIT | PETITIONER |
Prosecution File History of U.S. Patent No. 9,220,631, part 3 | Apr 16, 2021 | EXHIBIT | PETITIONER |
Prosecution File History of U.S. Patent No. 9,220,631, part 4 | Apr 16, 2021 | EXHIBIT | PETITIONER |
Declaration of Horst Koller under 37 C.F.R. �� 1.68 | Apr 16, 2021 | EXHIBIT | PETITIONER |
Curriculum Vitae of Horst Koller | Apr 16, 2021 | EXHIBIT | PETITIONER |
ITC Investigation No. 337-TA-1207, Staff���s Pre-Hearing Brief (public version) | Apr 16, 2021 | EXHIBIT | PETITIONER |
ITC Investigation No. 337-TA-1207, Complainant���s Unopposed Motion to Terminate | Apr 16, 2021 | EXHIBIT | PETITIONER |
PCT Patent Publication No. WO 2011/006877 to Sigg et al. (���Sigg���) | Apr 16, 2021 | EXHIBIT | PETITIONER |
PCT Patent Publication No. WO 2009/030976 to Boulange et al. (���Boulange���) | Apr 16, 2021 | EXHIBIT | PETITIONER |
Internet Archive WayBack Machine, March 7, 2011 Record of Drugs.com, Macugen Prescribing Information | Apr 16, 2021 | EXHIBIT | PETITIONER |
ITC Investigation No. 337-TA-1207, Initial Determination Terminating the Investigation | Apr 16, 2021 | EXHIBIT | PETITIONER |
Bhavnesh D. Shah & Bhupendra G. Prajapati, Pre-Filled Syringes: A New Concept, PHARMA BIO WORLD 51 (2009) (���Shah���) | Apr 16, 2021 | EXHIBIT | PETITIONER |
Arno Fries, Drug Delivery of Sensitive Biopharmaceuticals With Prefilled Syringes, 9(5) DRUG DELIVERY TECH. 22 (2009) (���Fries���) | Apr 16, 2021 | EXHIBIT | PETITIONER |
Thomas Schoenknecht, Prefilled Syringes: Why New Developments Are Important In Injectable Delivery Today, in PREFILLED SYRINGES INNOVATIONS THAT MEET THE GROWING DEMAND (OnDrugDelivery 2005) (���Schoenknecht���) | Apr 16, 2021 | EXHIBIT | PETITIONER |
U.S. Patent Publication No. 2012/0091026 to Chacornac et al. (���Chacornac���) | Apr 16, 2021 | EXHIBIT | PETITIONER |
Sandeep Nema & John D. Ludwig, Pharmaceutical Dosage Forms: Parenteral Medications, Volume 1: Formulation and Packaging (3rd ed. 2010) (���Nema Vol. 1���), part 1 | Apr 16, 2021 | EXHIBIT | PETITIONER |
Sandeep Nema & John D. Ludwig, Pharmaceutical Dosage Forms: Parenteral Medications, Volume 1: Formulation and Packaging (3rd ed. 2010) (���Nema Vol. 1���), part 2 | Apr 16, 2021 | EXHIBIT | PETITIONER |
Sandeep Nema & John D. Ludwig, Pharmaceutical Dosage Forms: Parenteral Medications, Volume 1: Formulation and Packaging (3rd ed. 2010) (���Nema Vol. 1���), part 3 | Apr 16, 2021 | EXHIBIT | PETITIONER |
Sandeep Nema & John D. Ludwig, Pharmaceutical Dosage Forms: Parenteral Medications, Volume 1: Formulation and Packaging (3rd ed. 2010) (���Nema Vol. 1���), part 4 | Apr 16, 2021 | EXHIBIT | PETITIONER |
Sandeep Nema & John D. Ludwig, Pharmaceutical Dosage Forms: Parenteral Medications, Volume 2: Facility Design, Sterilization and Processing (3rd ed. 2010) (���Nema Vol. 2���), part 1 | Apr 16, 2021 | EXHIBIT | PETITIONER |
Sandeep Nema & John D. Ludwig, Pharmaceutical Dosage Forms: Parenteral Medications, Volume 2: Facility Design, Sterilization and Processing (3rd ed. 2010) (���Nema Vol. 2���), part 2 | Apr 16, 2021 | EXHIBIT | PETITIONER |
Sandeep Nema & John D. Ludwig, Pharmaceutical Dosage Forms: Parenteral Medications, Volume 2: Facility Design, Sterilization and Processing (3rd ed. 2010) (���Nema Vol. 2���), part 3 | Apr 16, 2021 | EXHIBIT | PETITIONER |
Sandeep Nema & John D. Ludwig, Pharmaceutical Dosage Forms: Parenteral Medications, Volume 2: Facility Design, Sterilization and Processing (3rd ed. 2010) (���Nema Vol. 2���), part 4 | Apr 16, 2021 | EXHIBIT | PETITIONER |
PCT Patent Publication No. WO 2007/035621 to Scypinski et al. (���Scypinski���) | Apr 16, 2021 | EXHIBIT | PETITIONER |
U.S. Patent Publication No. 2003/0003014 to Metzner et al. (���Metzner���) | Apr 16, 2021 | EXHIBIT | PETITIONER |
U.S. Pharmacopeia, USP 789, Particulate Matter in Ophthalmic Solutions, USP 34 NF 29 (2011) | Apr 16, 2021 | EXHIBIT | PETITIONER |
U.S. Patent Publication No. 2011/276005 to Hioki et al. (���Hioki���) | Apr 16, 2021 | EXHIBIT | PETITIONER |
PCT Patent Publication No. WO 2007/149334 to Furfine et al. (���Furfine���) | Apr 16, 2021 | EXHIBIT | PETITIONER |
Michael W. Stewart et al., Fresh From the Pipeline Aflibercept, 11 NAT. REV. DRUG DISCOV. 269 (2012) (���Stewart���) | Apr 16, 2021 | EXHIBIT | PETITIONER |
U.S. Patent No. 7,060,269 to Baca et al. (���Baca���) | Apr 16, 2021 | EXHIBIT | PETITIONER |
Gerald McDonnel and Denver Russell, Antiseptics and Disinfectants: Activities, Action, and Resistance, Clinical Microbiology Review, (Jan. 1999). (���McDonnel���) | Apr 16, 2021 | EXHIBIT | PETITIONER |
Lu Liu et al., Silicone Oil Microdroplets and Protein Aggregates in Repackaged Bevacizumab and Ranibizumab: Effects of Long-term Storage and Product Mishandling, 52(2) INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 1023 (2011) (���Liu���) | Apr 16, 2021 | EXHIBIT | PETITIONER |
U.S. Patent No. 7,404,278 to Wittland et al. (���Wittland���) | Apr 16, 2021 | EXHIBIT | PETITIONER |
U.S. Food and Drug Administration, Lucentis�� Highlights of the Prescribing Information, (June 2010) (���Lucentis Label���) | Apr 16, 2021 | EXHIBIT | PETITIONER |
International Organization for Standardization, ISO 11040-4 Prefilled Syringes ��� Part 4: Glass Barrels for Injectables (2nd ed. 2007) (���ISO 11040-4���) | Apr 16, 2021 | EXHIBIT | PETITIONER |
PCT Patent Publication No. WO 2008/077155 to Lam et al. (���Lam���) | Apr 16, 2021 | EXHIBIT | PETITIONER |
James A. Dixon, et al. "VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration." Expert opinion on investigational drugs 18.10 (2009): 1573-1580. (���Dixon���) | Apr 16, 2021 | EXHIBIT | PETITIONER |
Declaration of Dr. Szilard Kiss under 37 C.F.R. �� 1.68 | Apr 16, 2021 | EXHIBIT | PETITIONER |
Curriculum Vitae of Dr. Szilard Kiss | Apr 16, 2021 | EXHIBIT | PETITIONER |
Declaration of James L. Mullins, Ph.D. | Apr 16, 2021 | EXHIBIT | PETITIONER |
Dow Corning�� 365 35% Dimethicone NF Emulsion ��� Frequently Asked Questions (2002) (���DC365 FAQ���) | Apr 16, 2021 | EXHIBIT | PETITIONER |
European Patent Application No. 12174860 to Novartis AG | Apr 16, 2021 | EXHIBIT | PETITIONER |
EXPUNGED | Apr 16, 2021 | EXHIBIT | PETITIONER |
Affidavit of Internet Archive Office Manager | Apr 16, 2021 | EXHIBIT | PETITIONER |
Internet Archive WayBack Machine, March 8, 2011 Record of Drugs.com, Welcome to Drugs.com | Apr 16, 2021 | EXHIBIT | PETITIONER |
Internet Archive WayBack Machine, February 25, 2011 Record of Drugs.com, FDA Professional Drug Information | Apr 16, 2021 | EXHIBIT | PETITIONER |
U.S. Food and Drug Administration, Eylea�� Highlights of the Prescribing Information, (November 2011) (���Eylea label���) | Apr 16, 2021 | EXHIBIT | PETITIONER |
U.S. Food and Drug Administration, Guidance for Industry: Container Closure Systems for Packaging Human and Biologics ��� Chemistry, Manufacturing, and Controls Documentation (May 1999) | Apr 16, 2021 | EXHIBIT | PETITIONER |
International Standard ISO-7864, Sterile hypodermic needles for single use, ISO 7864:1993(E) (���ISO-7864���) | Apr 16, 2021 | EXHIBIT | PETITIONER |
International Standard ISO-9626, Stainless steel needle tubing for the manufacture of medical devices ��� Amendment 1, ISO 9626:1991/Amd.1:2001(E) (���ISO-9626���) | Apr 16, 2021 | EXHIBIT | PETITIONER |
Advait Badkar, et al. Development of Biotechnology Products in Pre-filled Syringes: Technical Considerations and Approaches, American Association of Pharmaceutical Sciences, June 2011, 12(2): 564-572 (���Badkar���) | Apr 16, 2021 | EXHIBIT | PETITIONER |
William Leventon, ���Medical Device Sterilization: What Manufacturers Need to Know��� (MDDI online, Sept. 1, 2002) | Apr 16, 2021 | EXHIBIT | PETITIONER |
Pamela Carter, et al. The lowdown on low temperature sterilization for packaged devices, Healthcare Purchasing News, July 2008, 42-45. (���Carter���) | Apr 16, 2021 | EXHIBIT | PETITIONER |
U.S. Patent Publication No. 2005/0182370 to Hato (���Hato���) | Apr 16, 2021 | EXHIBIT | PETITIONER |
U.S. Department of Labor, Occupational Safety & Health Administration, Ethylene Oxide (EtO): Understanding OSHA���s Exposure monitoring Requirements, 2007 OSHA3325-01N (2007) | Apr 16, 2021 | EXHIBIT | PETITIONER |
Bryon Lambert, et al. Radiation and Ethylene Oxide Terminal Sterilization Experiences with Drug Eluting Stent Products, American Association of Pharmaceutical Sciences, December 2011, 12(4):1116-1126 (���Lambert���) | Apr 16, 2021 | EXHIBIT | PETITIONER |
IPR2020-1317, Paper No. 10, Patent Owner���s Preliminary Response | Apr 16, 2021 | EXHIBIT | PETITIONER |
IPR2020-1317, Paper No. 14, Patent Owner���s Sur-Reply | Apr 16, 2021 | EXHIBIT | PETITIONER |
John R. Gillis & Gregg Mosley, Validation of Pharmaceutical Processes, Chapter 16 ��� Validation of Ethylene Oxide Sterilization Processes (2011), pp.241-262 (���Gillis���) | Apr 16, 2021 | EXHIBIT | PETITIONER |
FDA Pesticide Analytical Manual Vol. 1, Chapter 6 - HPLC | Apr 16, 2021 | EXHIBIT | PETITIONER |
Kim, Leo & D���Amore, Patricia, ASIP Centennial Commentary ��� A Brief History of Anti-VEGF for the Treatment of Ocular Angiogenesis, The American Journal of Pathology, August 2012 182(2):376-379 | Apr 16, 2021 | EXHIBIT | PETITIONER |
J.S. Penn, et al. Vascular Endothelial Growth Factor in Eye Disease, Prog. Retin Eye Res., July 2008, 27(4):331-371. (���Penn2008���) | Apr 16, 2021 | EXHIBIT | PETITIONER |
U.S. Food and Drug Administration, Trivaris �� Highlights of the Prescribing Information, (May 2008) (���Trivaris label���) | Apr 16, 2021 | EXHIBIT | PETITIONER |
Internet Archive WayBack Machine, May 17, 2011 Record of U.S. Pharmacopeia, Understanding USP���NF | Apr 16, 2021 | EXHIBIT | PETITIONER |
Christine I. Falkner-Radler, et al. Needle Size in Intravitreal Injections-Preliminary Results of a Randomized Clinical Trial, AVRO Annual Meeting Abstract, March 2012, 54(884) | Apr 16, 2021 | EXHIBIT | PETITIONER |
Carsten H. Meyer, et al. Steps for a Safe Intravitreal Injection Technique ��� A look at how European and American approaches compare, Retinal Physician (July 1, 2009) | Apr 16, 2021 | EXHIBIT | PETITIONER |
Curriculum Vitae of James L. Mullins, Ph.D. | Apr 16, 2021 | EXHIBIT | PETITIONER |
DUPONT��� TYVEK�� COMPLIANCE TO ISO 11607-1:2006 (2011) | Apr 16, 2021 | EXHIBIT | PETITIONER |
Center for Drug Evaluation and Research, Application Number: 21-756, Approved Labeling, Macugen�� (pegaptanib sodium injection) (December 17, 2004) (���2004 Macugen Label���) | Apr 16, 2021 | EXHIBIT | PETITIONER |
Evangelos S. Gragoudas, et al. Pegaptanib for Neovascular Age-Related Macular Degeneration, New England Journal of Medicine 2004; 351:2805-16, with Supplementary Appendix. | Apr 16, 2021 | EXHIBIT | PETITIONER |
IPR2020-1317, Paper No. 15, Institution Decision | Apr 16, 2021 | EXHIBIT | PETITIONER |
Anita M. Leys, et al. Neovascular Growth Following Photodynamic Therapy for Choroidal Hemangioma and Neovascular Regression after Intravitreous Injection of Triamcinolone, Retina 2006; 26(6):693-7 | Apr 16, 2021 | EXHIBIT | PETITIONER |
Australian Government, Department of Health and Ageing, Australian Public Assessment Report for Aflibercept, (July 2012), part 1 | Apr 16, 2021 | EXHIBIT | PETITIONER |
Australian Government, Department of Health and Ageing, Australian Public Assessment Report for Aflibercept, (July 2012), part 2 | Apr 16, 2021 | EXHIBIT | PETITIONER |
Sophie J. Bakri and Noha S. Ekdawi, Intravitreal Silicone Oil Droplets after Intravitreal Drug Injections, Retina 2008; 20:996-1001 | Apr 16, 2021 | EXHIBIT | PETITIONER |
Jared S. Bee, et al. Effects of Surfaces and Leachables on the Stability of Biopharmaceuticals, Journal of Pharmaceutical Science (Oct. 2011) | Apr 16, 2021 | EXHIBIT | PETITIONER |
Michael Colucciello, Prefilled Syringe Delivery of Intravitreal Anti-VEGF Medications: Advantages for Patients and Physicians, Retinal Physician (Mar. 1, 2019) | Apr 16, 2021 | EXHIBIT | PETITIONER |
Declaration of Juergen Sigg (���Sigg Declaration���) | Apr 16, 2021 | EXHIBIT | PETITIONER |
Department of Health & Human Services, Macugen Approval Letter (Dec. 18, 2004) | Apr 16, 2021 | EXHIBIT | PETITIONER |
Lonny Wolgemuth, Challenges with Prefilled Syringes: The Parylene Solution, ONdrugDelivery (Oct. 2012) | Apr 16, 2021 | EXHIBIT | PETITIONER |
Therese M. Sassalos, Prefilled Syringes for Intravitreal Drug Delivery, Clinical Ophthalmology 2019:13 701-706 | Apr 16, 2021 | EXHIBIT | PETITIONER |
SCS Coating Systems, SCS Parylene Properties (2007) | Apr 16, 2021 | EXHIBIT | PETITIONER |
Lonny Wolgemuth, Assessing the Effects of Sterilization Methods on Parylene Coating, Medical Device & Diagnostic Industry, (Aug. 2002) | Apr 16, 2021 | EXHIBIT | PETITIONER |
David E. Overcashier, et al. Technical Considerations in the Development of Pre-filled Syringes for Protein Products, Am. Pharm. Rev. 2006;9(7): 77-83 (���Overcashier���) | Apr 16, 2021 | EXHIBIT | PETITIONER |
SDNY 20-5502 Docket | Apr 16, 2021 | EXHIBIT | PETITIONER |
Federal Court Statistics | Apr 16, 2021 | EXHIBIT | PETITIONER |
Novartis Letter to NDNY Court | Apr 16, 2021 | EXHIBIT | PETITIONER |
Mehmet S. Kocabora, et al. Intravitreal Silicone Oil Droplets Following Pegaptanib Injection, Acta Ophthalmologica 2010 | Apr 16, 2021 | EXHIBIT | PETITIONER |
Macugen Label (2008) | Apr 16, 2021 | EXHIBIT | PETITIONER |
U.S. Pharmacopeia, USP 789, Particulate Matter in Ophthalmic Solutions, USP 32 NF 27 (2009) | Apr 16, 2021 | EXHIBIT | PETITIONER |
Novartis NDNY Complaint | Apr 16, 2021 | EXHIBIT | PETITIONER |
Novartis Letter to SDNY Court | Apr 16, 2021 | EXHIBIT | PETITIONER |
ITC Investigation No. 337-TA-1207, Statement on the Public Interest by Proposed Respondent Regeneron Pharmaceuticals, Inc. | Apr 16, 2021 | EXHIBIT | PETITIONER |
ITC Investigation No. 337-TA-1207, Statement on the Public Interest by Szilard Kiss | Apr 16, 2021 | EXHIBIT | PETITIONER |
Nitin Rathore, et al. Variability in Syringe Components and its Impact on Functionality of Delivery Systems, PDA Journal of Pharmaceutical Science and Technology 2011, 65 468-480 (���Rathore���) | Apr 16, 2021 | EXHIBIT | PETITIONER |
PCT Patent Publication No. WO 2007/084765 to Deschatelets et al. | Apr 16, 2021 | EXHIBIT | PETITIONER |
PCT Patent Publication No. WO 97/44068 to Tack et al. | Apr 16, 2021 | EXHIBIT | PETITIONER |